Triumeq® (abacavir/dolutegravir/lamivudine) – Expanded indication, new warnings
November 21, 2017 – The FDA announced the approval of ViiV Healthcare’s Triumeq (abacavir/dolutegravir/lamivudine) tablets, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients weighing ≥ 40 kg.
Top